Clinical Trial Update: T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a T cell receptor therapy targeting MAGE-A3 in HLA-A*01 positive patients with metastatic cancer; the study is terminated with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Breast Cancer
• Cervical Cancer
• Melanoma
• Renal Cancer

Drugs mentioned

• T Cell Receptor Immunotherapy Targeting MAGE-A3 (TCR targeting MAGE-A3)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Breast Cancer, Cervical Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-06-05